. This proposal describes a 5-year NIH/R01 early stage investigator (ESI) application. The overall goal of my laboratory is to elucidate the roles of gene-environment regulation and intercellular signaling in perinatal heart chamber maturation and responses to stress during fetal to neonatal transition, a critical window for cardiac growth, particularly, in the context of congenital heart defects (CHDs). The proposed studies are based on my previous work and preliminary data demonstrating a novel regulatory circuit involving Wnt11 signaling and hypoxia in regulating chamber-specific growth uncovered by genome-wide analysis of perinatal cardiac transcriptome. Using targeted silencing of Wnt11 gene expression and systemic hypoxia induction in vivo, I have further established that Wnt11 regulates cardiomyocyte (CMC) proliferation likely through modulating Rb1 activity during normal and hypoxic transition as well as in cyanotic CHDs. In order to, mechanistically, determine whether Wnt11 affects chamber-specific growth, I have generated both gain of function and loss of function mouse models. The Wnt11-cKO mouse model with Tamoxifen-induced and cardiac-specific ablation of Wnt11 was established by utilizing a preexisting line carrying floxed Wnt11 (Wnt11Flox/Flox) and an ?MHC-MerCreMer line. Using this novel mouse model, I obtained strong evidence supporting that the Wnt11/Rb1 signaling is required for normal maturation of ventricular chambers. Importantly, this regulatory loop is disrupted by hypoxia more robustly in right ventricle (RV) than left ventricle (LV) in neonatal hearts and potentially leads to RV abnormalities in infants with cyanotic tetralogy of fallot (TOF). To achieve CMC specific gain of function for Wnt11, I also generated an AAV9 vector for CMC specific Wnt11 overexpression (Wnt11-OE). These studies were supported by an AHA career development award and an NIH/R56 (the High Priority Short-Term Project Award, or ?Bridge Award??). In this proposal, I plan to leverage our novel mouse models to establish the molecular mechanisms mediating Wnt11/Rb1 control of chamber-specific CMC proliferation in response to hypoxia, and to explore the pathological impact of this novel circuit in TOF.
In AIM 1, I will determine the role of Wnt11/Rb1 signaling in neonatal RV vs LV development and hypoxia response using Wnt11-cKO mouse model and AAV9-mediated Wnt11-OE, in combination with hypoxia exposure.
In AIM2, I will dissect the signaling cascade mediating Wnt11 function in neonatal rat ventricular myocytes (NRVMs) in vitro, and establish the biological relevance in the intact neonatal heart in vivo.
In AIM 3, I will examine the clinical relevance of the interplay between hypoxia and Wnt11/Rb1 in TOF pathogenesis after birth by characterizing a well-defined TOF cohort at the transcriptomic level. Accomplishing the proposed aims will establish a novel regulatory loop that may lead to chamber-specific therapies for newborns with CHDs. UCLA provides an ideal environment to achieve the proposed aims.
In our previous work1, we discovered an important role of Wnt11 in perinatal chamber specific growth in mice and in infants with cyanotic congenital heart defects (CHDs). Our goal in the current proposal is to determine how Wnt11 modulates chamber specific cardiomyocytes (CMCs) in response to perinatal hypoxia. Our long-term goal is to identify chamber specific therapies for newborn infants with cyanotic CHDs.
